2025 A Focus on Toxicity Management

aci-toxicity-management_-_Edited.png

friday, march 7, 2025 | 11 a.m.–3 P.M. ET
live via zoom webinar

Register Now


Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of toxicity management. FREE for healthcare professionals, students, patients and patient advocates.

New for 2025

  • Address insights on adverse events and autoimmunity, as well as the management of hyperinflammatory systems.
  • Discuss the latest approaches to minimizing the use of steroids to manage immune checkpoint inhibitor-related toxicities and reintroducing immune checkpoint inhibitors.
  • Provide approaches to optimize patient screening and education.
The 2025 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca and GSK (supporters as of February 18, 2025).

Program Organizers

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Marianne Davies, DNP, ACNP, AOCNP, FAAN
Smilow Cancer Hospital at Yale

Jordan McPherson, PharmD, MS, BCOP

Jordan McPherson, PharmD, MS, BCOP
University of Utah

Alexa Meara, MD

Alexa Meara, MD
The Ohio State University

Program Snapshot

Credits Available
Physician Education: 3.75 AMA PRA Category 1TM
Pharmacy Education: 3.75 contact hours (0.375 CEUs)
Nursing Education: 3.75 contact hours

Program Date & Location

Friday, March 7, 2025 at 11 a.m.-3 p.m. ET
Live via Zoom Webinar

Program Cost

FREE for healthcare professionals, students, patients and patient advocates.

Register for A Focus on Toxicity Management >

Program Agenda

11–11:05 a.m.

 

Welcome

11:05–11:35 a.m.

 

Navigating Drug Toxicity and Autoimmunity: Key Insights and Future Directions
Matthew Hadfield, DO – Brown University

11:35 a.m.–
12:15 p.m.

 
Steroid-Sparing Strategies: Exploring Mechanisms, Indications, and Practical Applications
Alexa Meara, MD – The Ohio State University
Jordan McPherson, PharmD, MS, BCOP – University of Utah

12:15–12:45 p.m.

 

Managing Hyperinflammatory Syndromes
Pankti Reid, MD, MPH – University of Chicago Medical Center

12:45–1:05 p.m.

 

irAEs: Prognostic Implications and Strategies for Rechallenging
Mingjia Li, MD – The Ohio State University

1:05–1:20 p.m.

 

Break

1:20–1:40 p.m.

 

Cancer Immunotherapy in Practice: Optimizing Patient Education and Screening Across Organizations
Marianne Davies, DNP, ACNP, AOCNP, FAANSmilow Cancer Hospital at Yale
Lisa Kottschade, APRN, MSN, CNP, FAPO – Mayo Clinic

1:40–2 p.m.

 

ASPIRE: Connecting Community Physicians for Collaboration and Support
Pauline Funchain, MD – Stanford University

2–3 p.m.

 

Faculty Panel

3 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2025 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.

  • Outline best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.

  • Describe management approaches for difficult or refractory immune-related adverse events.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosures and ADA Info

Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

SITC's Clinical Practice Guideline (CPG) Resources

Find information regarding disease-specific treatment algorithms and recommended administration of FDA-approved cancer immunotherapies. The guidelines are reviewed by expert panels on a recurring basis to account for newly available clinical trial data and FDA approvals.

The 2025 ACI series is jointly provided by Partners for Advancing Clinical Education and the Society for Immunotherapy of Cancer.